PeerView Internal Medicine CME/CNE/CPE Audio Podcast-logo

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Education Podcasts >

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
More Information

Location:

United States

Description:

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Language:

English


Episodes

Mitchell S. Cairo, MD - Attacking the Clinical Problem of VOD/SOS in HCT Recipients: Insights on Pathophysiology, Diagnosis, and Treatment

4/17/2019
More
In this activity, based on a live symposium held during the 2019 Transplantation and Cellular Therapy (TCT) Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in hematology-oncology explore new developments related to the changing clinical consensus for managing veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) as a post-transplant complication. In this program,...

Duration:00:52:25

Mark A. Socinski, MD - Expanding Options and Difficult Choices in the Initial Treatment of Advanced NSCLC: How to Personalize Treatment Decisions in the Era of Immuno-Oncology and Combinations

4/10/2019
More
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for...

Duration:00:50:46

Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

4/8/2019
More
Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that...

Duration:00:59:14

Madan H. Jagasia, MBBS, MS, MMHC - Innovative Therapies in Post-Transplant GVHD: Personal Insights From the Patient CaseBook

4/5/2019
More
Go online to PeerView.com/XYM860 to view the entire program with slides. This activity utilizes a “CaseBook” format, offering learners a collection of patient case scenarios from the experts’ personal repertoire paired with analyses of how the treatment landscape in acute and chronic graft-versus-host disease (GVHD) is evolving. Hematology-oncology and bone marrow transplant professionals take a deep dive into the underlying immunology of GVHD and the latest evidence with innovative...

Duration:00:48:49

Arjun Balar, MD - Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes

4/1/2019
More
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes

Duration:01:16:58

Mark S. Sulkowski, MD - Addressing the Evolving Opioid and HCV Epidemics Through Community Engagement and Education

3/25/2019
More
Go online to PeerView.com/QYB860 to view the entire program with slides. In this activity, which is based on recent live meetings held in Baltimore and Cambridge, Maryland, clinicians practicing on the front-lines of the intersecting hepatitis C and opioid epidemics offer thought-provoking perspectives on identifying HCV among people with substance use disorders who live in urban and rural healthcare settings and successfully engaging them in care to achieve better patient and community...

Duration:01:23:27

Luciano J. Costa, MD, PhD - Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact of Novel Platforms and Agent Classes Across the Spectrum of Care

3/20/2019
More
Go online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical findings...

Duration:00:32:53

Nathan H. Fowler, MD - Building Innovative Treatment Options for Patients With B-Cell Malignancies: Practical Insights on Clinical Evidence and Integration Strategies

3/15/2019
More
Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews...

Duration:00:53:35

Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

3/11/2019
More
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects...

Duration:00:32:40

Richard S. Finn, MD - Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

3/8/2019
More
Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

Duration:01:14:55

Anna F. Farago, MD, PhD - The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy

3/6/2019
More
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy

Duration:00:38:55

Roy H. Decker, MD, PhD - The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

3/4/2019
More
The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

Duration:00:58:06

Lynette M. Sholl, MD - Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

3/4/2019
More
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

Duration:01:20:49

Amir T. Fathi, MD - The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care

3/4/2019
More
The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care

Duration:00:42:10

Stewart J. Tepper, MD, FAHS - Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?

3/4/2019
More
Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?

Duration:01:01:33

Anjali Saqi, MD, MBA and Geoffrey R. Oxnard, MD - Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists

3/4/2019
More
Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists

Duration:00:48:38

Deborah I. Friedman, MD, MPH - Improving the Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention: How Is the Role of the Primary Care Clinician Evolving?

3/4/2019
More
Improving the Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention: How Is the Role of the Primary Care Clinician Evolving?

Duration:00:35:34

Edward B. Garon, MD, MS - Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice

3/4/2019
More
Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice

Duration:01:05:44

Guy Young, MD - Defining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A

3/1/2019
More
Defining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A

Duration:00:38:11

Edward S. Kim, MD, FACP - Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

2/27/2019
More
Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Duration:00:28:21